The group’s principal activities include developing, licensing and commercializing the manufacture and sale of human vaccines for diseases caused by Human Immunodeficiency Virus and other infectious agents. In September 2006, the group merged with Dauphin Technology, Inc. The group operates from the United States. The revenue of the group in the year 2006, were $852,905.
